These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37505171)

  • 21. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.
    Liang R; Li L; Li C; Gao Y; Liu W; Hu D; Sun Y
    J Thromb Thrombolysis; 2012 Jul; 34(1):120-5. PubMed ID: 22528326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population.
    Gaikwad T; Ghosh K; Kulkarni B; Kulkarni V; Ross C; Shetty S
    Eur J Pharmacol; 2013 Jun; 710(1-3):80-4. PubMed ID: 23602689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of CYP2C9, CYP4F2 and VKORC1 genetic polymorphisms on pharmacokinetics and pharmacodynamics of mean daily maintenance dose of warfarin in Chinese patients.
    Zhuang W; Wen W; Xuan B; Chen Y; Cao Y; Sun Z; Ma J
    Blood Coagul Fibrinolysis; 2015 Mar; 26(2):167-74. PubMed ID: 25304014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.
    El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM
    Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance.
    Azzam H; Elwakeel H; Awad I; El-Farahaty R; El-Gilany AH; El-Sharawy S
    Blood Coagul Fibrinolysis; 2016 Mar; 27(2):121-6. PubMed ID: 24978953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
    Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diversity of pharmacogenomic variants affecting warfarin metabolism in Sri Lankans.
    Ranasinghe P; Sirisena N; Senadeera V; Anandagoda G; Dissanayake VH
    Pharmacogenomics; 2022 Nov; 23(17):917-923. PubMed ID: 36285665
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacogenetic distribution of warfarin and its clinical significance in Korean patients during initial anticoagulation therapy.
    Kwon A; Jo SH; Im HJ; Jo YA; Park JY; Kang HJ; Kim HS; Cho HC; Lee YK
    J Thromb Thrombolysis; 2011 Nov; 32(4):467-73. PubMed ID: 21713378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
    Scott SA; Jaremko M; Lubitz SA; Kornreich R; Halperin JL; Desnick RJ
    Pharmacogenomics; 2009 Aug; 10(8):1243-55. PubMed ID: 19663669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.
    Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary OA
    Ir J Med Sci; 2014 Jun; 183(2):161-72. PubMed ID: 23800980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequency of CYP2C9 and VKORC1 gene polymorphisms and their influence on warfarin dose in Egyptian pediatric patients.
    Kamal El-Din MA; Farhan MS; El Shiha RI; El-Kaffas RM; Mousa SM
    Paediatr Drugs; 2014 Aug; 16(4):337-41. PubMed ID: 24797541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. VKORC1 and CYP2C9 genotype distribution in Asian countries.
    Gaikwad T; Ghosh K; Shetty S
    Thromb Res; 2014 Sep; 134(3):537-44. PubMed ID: 24908449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
    Johnson JA; Caudle KE; Gong L; Whirl-Carrillo M; Stein CM; Scott SA; Lee MT; Gage BF; Kimmel SE; Perera MA; Anderson JL; Pirmohamed M; Klein TE; Limdi NA; Cavallari LH; Wadelius M
    Clin Pharmacol Ther; 2017 Sep; 102(3):397-404. PubMed ID: 28198005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequencies of polymorphisms in CYP2C9 and VKORC1 genes influencing warfarin metabolism in Slovak population: implication for clinical practice.
    Krajciova L; Deziova L; Petrovic R; Luha J; Turcani P; Chandoga J
    Bratisl Lek Listy; 2014; 115(9):563-8. PubMed ID: 25318916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [FREQUENCY OF POLYMORPHISM OF VKORC1 AND CYP2C9 GENES IN TWO REGIONS OF GEORGIA].
    Jokhadze T; Kakauridze N; Buadze T; Gaiozishvili M; Lezhava T
    Georgian Med News; 2016 Jan; (250):46-51. PubMed ID: 26870974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of gene polymorphims on the warfarin treatment at initial stage.
    Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
    Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of a warfarin dosing algorithm including CYP2C9, VKORC1, and CYP4F2 polymorphisms and non-genetic determinants for the Iranian population.
    Farajzadeh-Dehkordi M; Samiee-Rad F; Farzam SS; Javadi A; Cheraghi S; Hamedi-Asl D; Rahmani B
    Pharmacol Rep; 2023 Jun; 75(3):695-704. PubMed ID: 37039974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of VKORC1, CYP2C9, and CYP4F2 Polymorphisms on Optimal Warfarin Dose: Does Ethnicity Matters?
    Li JX; Kim MH; Song K; Guo LZ; Jin EZ; Kim SJ; Lee KM; Serebruany V
    Am J Ther; 2021 Jul-Aug 01; 28(4):e461-e468. PubMed ID: 34228652
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.